Mechanisms of sympathetic activation in heart failure

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 12, 2006, Pages 1269-1274

  Watson, A M D ^a   Hood, S G ^a   May, C N ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin; Baroreceptors; Cardiac sympathetic nerve activity; Chemoreceptors; Renal sympathetic nerve activity

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MESSENGER RNA; NATRIURETIC FACTOR; NEUROPEPTIDE Y; NORADRENALIN;

CHEMORECEPTOR; CLINICAL FEATURE; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; HEART FAILURE; HEART INNERVATION; HUMAN; HYPERTENSION; INOTROPISM; ISCHEMIC HEART DISEASE; NONHUMAN; PRESSORECEPTOR; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYMPATHETIC TONE;

ANGIOTENSIN II; ANIMALS; BAROREFLEX; HEART FAILURE, CONGESTIVE; HUMANS; NEUROTRANSMITTER AGENTS; SYMPATHETIC NERVOUS SYSTEM;

EID: 33845542345     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04523.x     Document Type: Conference Paper

References (73)

1. Australian Institute of Health and Welfare. Heart, Stroke and Vascular Diseases: Australian Facts: Cardiovascular Disease Series No. 22. AIHW catalogue No. CVD 27. AIHW and National Heart Foundation of Australia, Canberra. 2004.
2. Levy D, Kenchaiah S, Larson MG et al. Long-term trends in the incidence of and survival with heart failure. N. Engl. J. Med. 2002; 347: 1397-402.
3. Packer M. New concepts in the pathophysiology of heart failure. Beneficial and deleterious interaction of endogenous haemodynamic and neurohormonal mechanisms. J. Intern. Med. 1996; 239: 327-33.
4. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N. Engl. J. Med. 1999; 341: 577-85.
5. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart-failure. Ann. Intern. Med. 1984; 101: 370-7.
6. Ferguson DW. Sympathetic mechanisms in heart failure. Circulation 1993; 87 (Suppl. VII): VII68-75.
7. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63: 645-51.
8. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 1991; 325: 293-302.
9. Funder JW. ACE inhibitors and mineralocorticoid receptor blockade in patients with congestive heart failure. Curr. Diab. Rep. 2005; 5: 36-40.
10. Burnett JC Jr, Kao PC, Hu DC et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986; 231: 1145-7.
11. Clavell A, Stingo A, Margulies K, Lerman A, Underwood D, Burnett JC. Physiological significance of endothelin: Its role in congestive-heart-failure. Circulation 1993; 87: 45-50.
12. Richards A, Nicholls M, Lainchbury J, Fisher S, Yandle T. Plasma urotensin II in heart failure. Lancet 2002; 360: 545-6.
13. Brunner-La Rocca HP, Kaye DM, Woods RL, Hastings J, Esler MD. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J. Am. Coll. Cardiol. 2001; 37: 1221-7.
14. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: Evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986; 73: 615-21.
15. Esler M, Jennings G, Korner P et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 1988; 11: 3-20.
16. Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation 1997; 95: 169-75.
17. Meredith IT, Eisenhofer G, Lambert GW, Dewar EM, Jennings GL, Esler MD. Cardiac sympathetic nervous activity in congestive heart failure. Evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation 1993; 88: 136-45.
18. Eisenhofer G, Friberg P, Rundqvist B et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996; 93: 1667-76.
19. Ninomiya I, Matsukawa K, Nishiura N. Central and baroreflex control of sympathetic nerve activity to the heart and kidney in a daily life of the cat. Clin. Exp. Theory Pract. 1988; A10: 19-31.
20. Karim F, Kidd C, Malpus CM, Penna PE. The effects of stimulation of the left atrial receptors on sympathetic efferent nerve activity. J. Physiol. 1972; 227: 243-60.
21. Matsukawa K, Ninomiya I, Nishiura N. Effects of anesthesia on cardiac and renal sympathetic nerve activities and plasma catecholamines. Am. J. Physiol. 1993; 265: R792-7.
22. Grassi G, Seravalle G, Cattaneo BM et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 1995; 92: 3206-11.
23. Ferguson DW, Berg WJ, Roach PJ, Oren RM, Mark AL. Effects of heart failure on baroreflex control of sympathetic neural activity. Am. J. Cardiol. 1992; 69: 523-31.
24. Liu JL, Pliquett RU, Brewer E, Cornish KG, Shen YT, Zucker IH. Chronic endothelin-1 blockade reduces sympathetic nerve activity in rabbits with heart failure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001; 280: R1906-13.
25. DiBona GF, Herman PJ, Sawin LL. Neural control of renal function in edema-forming states. Am. J. Physiol. 1988; 254: R1017-24.
26. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J. Am. Coll. Cardiol. 1995; 26: 1257-63.
27. Reiken S, Gaburjakova M, Gaburjakova J et al. Beta-adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure. Circulation 2001; 104: 2843-8.
28. Lehnart SE, Wehrens XH, Marks AR. Calstabin deficiency, ryanodine receptors, and sudden cardiac death. Biochem. Biophys. Res. Commun. 2004; 322: 1267-79.
29. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001; 104: 569-80.
30. Meredith IT, Broughton A, Jennings GL, Esler MD. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N. Engl. J. Med. 1991; 325: 618-24.
31. Du XJ, Cox HS, Dart AM, Esler MD. Sympathetic activation triggers ventricular arrhythmias in rat heart with chronic infarction and failure. Cardiovasc. Res. 1999; 43: 919-29.
32. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 2001; 344: 1651-8.
33. Mann DL, Kent RL, Parsons B, Cooper Gt. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992; 85: 790-804.
34. Keys JR, Koch WJ. The adrenergic pathway and heart failure. Recent Prog. Horm. Res. 2004; 59: 13-30.
35. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ. Res. 2003; 93: 896-906.
36. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558-69.
37. Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G, Esler MD. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J. Am. Coll. Cardiol. 1994; 23: 570-8.
38. Eckberg DL, Drabinsky M, Braunwald E. Defective cardiac parasympathetic control in patients with heart disease. N. Engl. J. Med. 1971; 285: 877-83.
39. Porter TR, Eckberg DL, Fritsch JM et al. Autonomic pathophysiology in heart failure patients. Sympathetic-cholinergic interrelations. J. Clin. Invest. 1990; 85: 1362-71.
40. Dunlap ME, Bibevski S, Rosenberry TL, Ernsberger P. Mechanisms of altered vagal control in heart failure: Influence of muscarinic receptors and acetylcholinesterase activity. Am. J. Physiol. Heart Circ. Physiol. 2003; 285: H1632-40.
41. DiBona GF, Sawin LL. Increased renal nerve activity in cardiac failure: Arterial vs. cardiac baroreflex impairment. Am. J. Physiol. 1995; 268: R112-16.
42. Sun SY, Wang W, Zucker IH, Schultz HD. Enhanced activity of carotid body chemoreceptors in rabbits with heart failure: Role of nitric oxide. J. Appl. Physiol. 1999; 86: 1273-82.
43. Zucker IH, Wang W, Pliquett RU, Liu JL, Patel KP. The regulation of sympathetic outflow in heart failure. The roles of angiotensin II, nitric oxide, and exercise training. Ann. N.Y. Acad. Sci. 2001; 940: 431-43.
44. Felder RB, Francis J, Weiss RM, Zhang ZH, Wei SG, Johnson AK. Neurohumoral regulation in ischemia-induced heart failure. Role of the forebrain. Ann. N.Y. Acad. Sci. 2001; 940: 444-53.
45. Dibner-Dunlap ME, Thames MD. Baroreflex control of renal sympathetic nerve activity is preserved in heart failure despite reduced arterial baroreceptor sensitivity. Circ. Res. 1989; 65: 1526-35.
46. Leimbach Jr WN, Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986; 73: 913-19.
47. Mark AL. Sympathetic dysregulation in heart failure: Mechanisms and therapy. Clin. Cardiol. 1995; 18: I3-8.
48. Liu JL, Irvine S, Reid IA, Patel KP, Zucker IH. Chronic exercise reduces sympathetic nerve activity in rabbits with pacing-induced heart failure: A role for angiotensin II. Circulation 2000; 102: 1854-62.
49. Dibner-Dunlap ME, Smith ML, Kinugawa T, Thames MD. Enalaprilat augments arterial and cardiopulmonary baroreflex control of sympathetic nerve activity in patients with heart failure. J. Am. Coll. Cardiol. 1996; 27: 358-64.
50. Zucker IH, Gorman AJ, Cornish KG, Lang M. Imparied atrial receptor modulation or renal nerve activity in dogs with chronic volume overload. Cardiovasc. Res. 1985; 19: 411-18.
51. Brändle M, Patel KP, Wang W, Zucker IH. Hemodynamic and norepinephrine responses to pacing-induced heart failure in conscious sinoaortic-denervated dogs. J. Appl. Physiol. 1996; 81: 1855-62.
52. Bainbridge FA. The influence of venous filling upon the rate of the heart. J. Physiol. 1915; 50: 65-84.
53. Akama H, McGrath BP, Badoer E. Volume expansion fails to normally activate neural pathways in the brain of conscious rabbits with heart failure. J. Auton. Nerv. Syst. 1998; 73: 54-62.
54. Kaye DM, Jennings GL, Dart AM, Esler MD. Differential effect of acute baroreceptor unloading on cardiac and systemic sympathetic tone in congestive heart failure. J. Am. Coll. Cardiol. 1998; 31: 583-7.
55. Azevedo ER, Newton GE, Floras JS, Parker JD. Reducing cardiac filling pressure lowers norepinephrine spillover in patients with chronic heart failure. Circulation 2000; 101: 2053-9.
56. Levett JM, Marinelli CC, Lund DD et al. Effects of beta-blockade on neurohumoral responses and neurochemical markers in pacing-induced heart failure. Am. J. Physiol. 1994; 266: H468-75.
57. Wang W, Zucker IH. Cardiac sympathetic afferent reflex in dogs with congestive heart failure. Am. J. Physiol. 1996; 271: R751-6.
58. 1 receptors are involved in the enhanced cardiac sympathetic afferent reflex in rats with chronic heart failure. Basic Res. Cardiol. 2002; 97: 320-6.
59. Liu JL, Murakami H, Sanderford M, Bishop VS, Zucker IH. ANG II and baroreflex function in rabbits with CHF and lesions of the area postrema. Am. J. Physiol. 1999; 277: H342-50.
60. Dampney R, Coleman M, Fontes M et al. Central mechanisms underlying short- and long-term regulation of the cardiovascular system. Clin. Exp. Pharmacol. Physiol. 2002; 29: 261-8.
61. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am. J. Physiol. 1992; 262: E763-78.
62. Grassi G, Cattaneo BM, Seravalle G et al. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 1997; 96: 1173-9.
63. Young JB, Dunlap ME, Pfeffer MA et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: Results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004; 110: 2618-26.
64. Miller LW. Limitations of current medical therapies for the treatment of heart failure. Rev. Cardiovasc. Med. 2003; 4 (Suppl. 2): S21-9.
65. Inoko M, Fujita M, Nakae I et al. Effect of angiotensin-converting enzyme inhibition on sympathetic tone in patients with mild to moderate heart failure. Jpn. Circ. J. 2001; 65: 395-8.
66. DiBona GF, Jones SY, Brooks VL. ANG II receptor blockade and arterial baroreflex regulation of renal nerve activity in cardiac failure. Am. J. Physiol. 1995; 269: R1189-96.
67. 1 receptors enhances baroreflex control of heart rate in conscious rabbits with heart failure. Am. J. Physiol. 1996; 271: R303-9.
68. Murakami H, Liu JL, Zucker IH. Angiotensin II blockade enhances baroreflex control of sympathetic outflow in heart failure. Hypertension 1997; 29: 564-9.
69. Watson AMD, Mogulkoc R, McAllen RM, May CN. Stimulation of cardiac sympathetic nerve activity by central angiotensinergic mechanisms in conscious sheep. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004; 286: R1051-6.
70. May CN, McAllen RM. Baroreceptor-independent renal nerve inhibition by intracerebroventricular angiotensin II in conscious sheep. Am. J. Physiol. 1997; 273: R560-7.
71. Zhang W, Huang BS, Leenen FH. Brain renin-angiotensin system and sympathetic hyperactivity in rats after myocardial infarction. Am. J. Physiol. 1999; 276: H1608-15.
72. Zucker IH, Schultz HD, Li YF, Wang Y, Wang W, Patel KP. The origin of sympathetic outflow in heart failure. The roles of angiotensin II and nitric oxide. Prog. Biophys. Mol. Biol. 2004; 84: 217-32.
73. Gao L, Wang W, Li YL et al. Superoxide mediates sympathoexcitation in heart failure: Roles of angiotensin II and NAD(P)H oxidase. Circ. Res. 2004; 95: 937-44.